CADTH | Evidence Driven
CADTH | Evidence Driven

Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1009-000

Question


  1. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with early breast cancer (EBC)?

  2. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic breast cancer (MBC)?

  3. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic gastric cancer (MGC)?


Key Message

No relevant literature was identified regarding the clinical effectiveness of switching from Ogivri or other biosimilars to Herceptin for patients with EBC, MBC or MGC.


Files

Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri Rapid Response February 4, 2019 View PDF

Related Content

Last Updated : February 4, 2019